An activating intragenic deletion in NOTCH1 in human T-ALL.

Oncogenic activating mutations in NOTCH1 occur in more than 50% of T-cell acute lymphoblastic leukemias (T-ALLs). In the present study, we describe a novel mechanism of NOTCH1 activation in T-ALL in which a deletion removing the 5' portion of NOTCH1 abolishes the negative regulatory control of the extracellular domain and leads to constitutively active NOTCH1 signaling. Polypeptides translated from truncated transcripts encoded by the NOTCH1 deletion allele retain the transmembrane domain of the receptor and are constitutively cleaved by the γ-secretase complex, resulting in high levels of NOTCH1 signaling that can be effectively blocked by γ-secretase inhibitors. Our results expand the spectrum of oncogenic lesions activating NOTCH1 signaling in human T-ALL.

[1]  Iannis Aifantis,et al.  Oncogenic and tumor suppressor functions of Notch in cancer: it’s NOTCH what you think , 2011, The Journal of experimental medicine.

[2]  F. Radtke,et al.  Notch in T-ALL: new players in a complex disease. , 2011, Trends in immunology.

[3]  W. Pear,et al.  Critical roles of NOTCH1 in acute T-cell lymphoblastic leukemia , 2011, International journal of hematology.

[4]  A. Ferrando,et al.  Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. , 2011, Blood reviews.

[5]  J. Aster,et al.  Notch signalling in T‐cell lymphoblastic leukaemia/lymphoma and other haematological malignancies , 2011, The Journal of pathology.

[6]  J. Aster,et al.  Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. , 2010, Blood.

[7]  J. Aster,et al.  Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. , 2010, Blood.

[8]  A. Ferrando,et al.  NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. , 2008, Blood.

[9]  A. Ferrando,et al.  CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to γ-secretase inhibitors , 2006, Leukemia.

[10]  J. Aster,et al.  Leukemia-Associated Mutations within the NOTCH1 Heterodimerization Domain Fall into at Least Two Distinct Mechanistic Classes , 2006, Molecular and Cellular Biology.

[11]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[12]  A. Ferrando,et al.  Gene expression profiling in T-cell acute lymphoblastic leukemia. , 2003, Seminars in hematology.

[13]  Hideki Ukai,et al.  Radiation-induced deletions in the 5' end region of Notch1 lead to the formation of truncated proteins and are involved in the development of mouse thymic lymphomas. , 2003, Carcinogenesis.

[14]  A. Ferrando,et al.  Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. , 2000, Seminars in hematology.

[15]  H. Macdonald,et al.  Deficient T cell fate specification in mice with an induced inactivation of Notch1. , 1999, Immunity.

[16]  A. Ferrando,et al.  The role of NOTCH1 signaling in T-ALL. , 2009, Hematology. American Society of Hematology. Education Program.